Adlai Nortye Group Ltd. (ANL) stock analysis

Healthcare · Biotechnology

From the 20-F filed 2026-04-10

How it makes money

Adlai Nortye earns no revenue from drug sales at this time.

No one pays the company currently. Future revenue will be driven by clinical success and regulatory approval of its cancer therapies.

What protects it: the moat

Management claims a dual R&D presence in the U.S. and China protects its pipeline.

The company uses research centers in New Jersey and Hangzhou to identify new drugs. This dual presence is intended to help the company recruit top talent and develop a strong pipeline.

What growth costs

The company incurred net losses of US$109.2 million, US$51.9 million, and US$35.5 million in recent years.

These losses reflect the heavy costs of developing new cancer therapies. The company expects these expenses to increase as it expands clinical trials and builds commercial infrastructure.

What could damage it

An inability to secure funding could prevent the company from completing necessary clinical trials.

The company currently operates at a loss and has no revenue. Without constant infusions of cash, it cannot afford the high costs of testing its drugs in humans.

About Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Other companies in Biotechnology